ARCH Venture Partners XII, LLC - Sep 28, 2023 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role: 10%+ Owner
Signature: ARCH Venture Fund XII, L.P. By: ARCH Venture Partners XII, L.P., its General Partner By: ARCH Venture Partners XII, LLC, its General Partner By: /s/ Mark McDonnell, as Attorney-in-Fact
Stock symbol: NMRA
Transactions as of: Sep 28, 2023
Transactions value $: $1,046,848
Form type: 4
Date filed: 9/29/2023, 06:53 PM
Previous filing: Sep 27, 2023
Next filing: Nov 7, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NMRA	Common Stock	Purchase	$220K	+16.8K	+0.45%	$13.06^*	3.8M	Sep 28, 2023	By ARCH Venture Fund XII, L.P.	F1, F4, F5
transaction	NMRA	Common Stock	Purchase	$344K	+25.1K	+0.66%	$13.69^*	3.83M	Sep 28, 2023	By ARCH Venture Fund XII, L.P.	F2, F4, F5
transaction	NMRA	Common Stock	Purchase	$483K	+34.6K	+0.9%	$13.98^*	3.86M	Sep 29, 2023	By ARCH Venture Fund XII, L.P.	F3, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.34 to $13.33, inclusive. The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.
F2	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.34 to $14.23, inclusive.
F3	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.48 to $14.11, inclusive.
F4	Beneficial ownership consists of 3,859,898 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
F5	As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023.

Remarks:

This Form 4 is filed jointly by ARCH XII, AVP XII LP, AVP XII LLC, Robert Nelsen, Steven Gillis, Keith Crandell (collectively, the "Reporting Persons"). Kristina Burow has direct ownership of common stock and is filing her own Form 4 separately.